trifluridine has been researched along with Local Neoplasm Recurrence in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (35.29) | 24.3611 |
| 2020's | 11 (64.71) | 2.80 |
| Authors | Studies |
|---|---|
| Ananda, S; Banks, S; Dunn, C; Gard, G; Gately, L; Gibbs, P; Jalali, A; Jennens, R; Khattak, A; Kosmider, S; Lee, B; Lee, M; Lim, L; Loft, M; McKendrick, J; Shapiro, JD; Tie, J; Wong, HL; Wong, R; Yeung, JM | 1 |
| Hara, H; Hironaka, S; Horimatsu, T; Ishihara, R; Kasai, H; Kato, K; Kawaguchi, A; Kikuchi, O; Kojima, T; Mori, Y; Mukai, K; Muto, M; Tada, H; Tsushima, T; Uozumi, R | 1 |
| Boku, N; Hirano, H; Iwasa, S; Okita, N; Oshima, K; Shoji, H; Takashima, A | 1 |
| Bebyn, M; Koper, A; Koper, K; Śledzińska, P; Wileński, S | 1 |
| Krogh, M; Möller, S; Petersen, LN; Pfeiffer, P; Poulsen, LØ; Qvortrup, C; Thomsen, KG; Winther, SB; Yilmaz, M; Zitnjak, D | 1 |
| Hata, T; Kagawa, Y; Kato, T; Katsura, Y; Kawai, K; Masuzawa, T; Mori, R; Murakami, K; Murata, K; Naito, A; Nose, Y; Ohmura, Y; Sakamoto, T; Takeda, Y; Takeno, A | 1 |
| Hamada, S; Ikeda, J; Komatsu, S; Konishi, T; Matsubara, D; Shibata, R; Shimomura, K; Shioaki, Y; Soga, K; Taniguchi, F | 1 |
| Akamatsu, H; Asaoka, T; Furukawa, K; Imasato, M; Inui, M; Iwamoto, K; Kishi, K; Mikamori, M; Moon, J; Naito, A; Nakahara, Y; Ohtsuka, M; Wada, R; Zenitani, S | 1 |
| Amagasa, H; Ami, K; Ando, M; Fukuda, A; Gan, S; Ganno, H; Iida, S; Imai, K; Kajiyama, D; Kawaguchi, M; Maeda, F; Motoyama, K; Okano, Y; Tokitou, F; Yamada, A | 1 |
| Burge, M; Dean, A; Gibbs, P; Jalali, A; Lee, B; Lee, M; Lim, SH; Min, ST; Nott, L; Roohullah, A; Shapiro, J; Steel, S; Tognela, A; Wong, HL; Wong, R; Yip, D; Zimet, A | 1 |
| Aleshin, A; Billings, PR; Ebi, H; Kato, T; Kotani, D; Mishima, S; Mori, M; Nakamura, Y; Oki, E; Rabinowitz, M; Sawada, K; Shirasu, H; Takemasa, I; Taniguchi, H; Yamanaka, T; Yoshino, T; Yukami, H | 1 |
| Iwai, M; Kimura, M; Teramachi, H; Usami, E; Yoshimura, T | 1 |
| Arnold, D; Moreno Vera, S; Mounedji, N; Prager, GW; Quintela, A; Stein, A; Taieb, J | 1 |
| Ikeda, Y; Iwai, M; Kawachi, S; Kimura, M; Mitsuoka, M; Usami, E; Yasue, F; Yoshimura, T | 1 |
| Kimura, M; Teramachi, H; Usami, E; Yoshimura, T | 1 |
| Goldberg, R | 1 |
| Asano, H; Go, M; Ito, D; Iwai, M; Kimura, M; Teramachi, H; Usami, E; Yoshimura, T | 1 |
1 review(s) available for trifluridine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review.
Topics: Colorectal Neoplasms; Disease Progression; Drug Combinations; Drugs, Investigational; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Phenylurea Compounds; Pyridines; Pyrrolidines; Thymine; Trifluridine; Uracil | 2018 |
3 trial(s) available for trifluridine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Multicenter phase II study of trifluridine/tipiracil for esophageal squamous carcinoma refractory/intolerant to 5-fluorouracil, platinum compounds, and taxanes: the ECTAS study.
Topics: Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Japan; Neoplasm Recurrence, Local; Platinum Compounds; Pyrrolidines; Taxoids; Trifluridine | 2022 |
TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Pyrrolidines; Salvage Therapy; Survival Rate; Thymine; Trifluridine; Uracil | 2020 |
CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Circulating Tumor DNA; Colonic Neoplasms; Colorectal Neoplasms; Double-Blind Method; Humans; Japan; Neoplasm Recurrence, Local; Oxaliplatin; Prospective Studies; Pyrrolidines; Thymine; Trifluridine | 2021 |
13 other study(ies) available for trifluridine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Middle Aged; Neoplasm Recurrence, Local; Pyrrolidines; Rectal Neoplasms; Retrospective Studies; Thymine; Trifluridine; Uracil | 2022 |
Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Humans; Neoplasm Recurrence, Local; Phenylurea Compounds; Pyridines; Pyrrolidines; Thymine; Trifluridine; Uracil | 2022 |
Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Neoplasm Recurrence, Local; Prognosis; Pyrrolidines; Rectal Neoplasms; Retrospective Studies; Trifluridine; Uracil | 2023 |
Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Prognosis; Pyrrolidines; Retrospective Studies; Survival Rate; Thymine; Trifluridine | 2020 |
[Long-Term Survivor with Recurrent Gastric Cancer Using Trifluridine/Tipiracil as a Late-Line Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Neoplasm Recurrence, Local; Pyrrolidines; Stomach Neoplasms; Survivors; Thymine; Trifluridine; Uracil | 2020 |
[Case Series of the TAS-102 plus Bevacizumab(Bev)Combination Therapy in Unresectable Advanced Colorectal Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations; Fluorouracil; Humans; Neoplasm Recurrence, Local; Pyrrolidines; Thymine; Treatment Outcome; Trifluridine | 2020 |
[Two Cases of Metastatic Colorectal Cancer Treated with TAS-102 plus Bevacizumab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations; Humans; Neoplasm Recurrence, Local; Pyrrolidines; Thymine; Trifluridine; Uracil | 2021 |
Patient demographics and management landscape of metastatic colorectal cancer in the third-line setting: Real-world data in an australian population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Colonic Neoplasms; Colorectal Neoplasms; Demography; ErbB Receptors; Humans; Neoplasm Recurrence, Local; Proto-Oncogene Proteins p21(ras); Rectal Neoplasms; Retrospective Studies; Trifluridine | 2022 |
Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Prognosis; Pyrrolidines; Risk Factors; Survival Analysis; Thymine; Trifluridine; Uracil | 2017 |
Risk factors contributing to the development of neutropenia in patients receiving oral trifluridine-tipiracil (TAS-102) chemotherapy for advanced/recurrent colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Creatinine; Drug Combinations; Female; Humans; Leukocyte Count; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Neutrophils; Pyrrolidines; Retrospective Studies; Risk Factors; Thymine; Trifluridine; Uracil | 2018 |
Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Pyrrolidines; Retrospective Studies; Tablets; Thymine; Treatment Outcome; Trifluridine; Uracil | 2019 |
Emerging phase 3 data in relapsed/refractory metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Humans; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Phenylurea Compounds; Pyridines; Pyrrolidines; Retreatment; Thymine; Treatment Outcome; Trifluridine; Uracil | 2016 |
Safety of an oral anticancer agent (trifluridine/tipiracil combination tablet) in patients with advanced and recurrent colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Drug Combinations; Female; Humans; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neutropenia; Patient Safety; Pyrrolidines; Retrospective Studies; Tablets; Thymine; Trifluridine; Uracil; Vomiting | 2016 |